Show simple item record

dc.contributor.authorSrivastava, Sukrit
dc.contributor.authorVerma, Sonia
dc.contributor.authorKamthania, Mohit
dc.contributor.authorKaur, Rupinder
dc.contributor.authorBadyal, Ruchi Kiran
dc.contributor.authorSaxena, Ajay Kumar
dc.contributor.authorShin, Ho-Joon
dc.contributor.authorKolbe, Michael
dc.contributor.authorPandey, Kailash C
dc.date.accessioned2021-04-30T13:18:28Z
dc.date.available2021-04-30T13:18:28Z
dc.date.issued2020-06-19
dc.identifier.citationJMIR Bioinform Biotech. 2020 Jun 19;1(1):e19371. doi: 10.2196/19371.en_US
dc.identifier.pmid32776022
dc.identifier.doi10.2196/19371
dc.identifier.urihttp://hdl.handle.net/10033/622852
dc.description.abstractBoth designed MEVs are composed of CTL and HTL epitopes screened from 11 Open Reading Frame (ORF), structural and nonstructural proteins of the SARS-CoV-2 proteome. Both MEVs also carry potential B-cell linear and discontinuous epitopes as well as interferon gamma-inducing epitopes. To enhance the immune response of our vaccine design, truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1 was used as an adjuvant at the N termini of both MEVs. The tertiary models for both the designed MEVs were generated, refined, and further analyzed for stable molecular interaction with toll-like receptor 3. Codon-biased complementary DNA (cDNA) was generated for both MEVs and analyzed in silico for high level expression in a mammalian (human) host cell line.en_US
dc.language.isoenen_US
dc.publisher: JMIR Publications Inc.en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19en_US
dc.subjectcoronavirusen_US
dc.subjectepitopeen_US
dc.subjecthuman transporter associated with antigen processing (TAP)en_US
dc.subjectimmunoinformaticsen_US
dc.subjectmolecular docking, molecular dynamics simulationen_US
dc.subjectmultiepitope vaccineen_US
dc.subjectsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjecttoll-like receptor (TLR)en_US
dc.titleStructural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.en_US
dc.typeArticleen_US
dc.identifier.eissn2563-3570
dc.contributor.departmentCSSB, Centre for Structural Systembiologie, Notkestr.85, 22607 Hamburg. Germany.en_US
dc.identifier.journalJMIR bioinformatics and biotechnologyen_US
dc.source.volume1
dc.source.issue1
dc.source.beginpagee19371
dc.source.endpage
refterms.dateFOA2021-04-30T13:18:29Z
dc.source.journaltitleJMIR bioinformatics and biotechnology
dc.source.countryCanada


Files in this item

Thumbnail
Name:
Srivastava et al.pdf
Size:
1.528Mb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International